Communications

(Dec. 5, 2025) – Respiratory syncytial virus is a leading cause of infant hospitalization and admission to intensive care units. In its Nov. 20, 2025, Morbidity and Mortality Weekly Report, the Centers for Disease Control and Prevention outlines the effectiveness of nirsevimab, a long-acting monoclonal antibody, against RSV-associated lower respiratory tract infection and hospitalization among infants. Nirsevimab is currently recommended by the CDC to prevent severe RSV-related disease. In this multicenter case-control investigation described in MMWR, nirsevimab was 80 percent effective at preventing RSV-associated ICU admission and 83 percent effective at preventing acute respiratory failure among infants admitted to an ICU with respiratory symptoms during their first RSV season. The data provided by the CDC support recommendations to use nirsevimab as a prevention strategy to protect infants from severe outcomes of RSV infection.
--Karen Braman